Serum CCL11 Levels in Benign Prostatic Hyperplasia and Prostate Cancer
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose: CC-chemokine ligand 11 (CCL11; eotaxin-1), an eosinophil chemoat-tractant chemokine, has been proposed as a serum marker for prostate cancer (PCa) by two research groups. We investigated the usefulness of CCL11 in diagnosing prostatic diseases, such as benign prostatic hyperplasia (BPH) and PCa.Materials and Methods: CCL11 was measured in the sera of 139 men with BPH, 44 men with PCa, and 45 control men attending an outpatient health-screening clinic. A commercial enzyme-linked immunosorbent assay kit was used to measure CCL11.Results: CCL11 concentrations were significantly higher in men with BPH and PCa than in normal men (72.9±3.15 and 80.0±4.91 pg/ml vs. 57.6±8.24). In addition, a receiver operating characteristic (ROC) analysis of serum CCL11 levels showed that the areas under the ROC curves were 0.661 (p=0.001) and 0.654 (p=0.012) for BPH and PCa, respectively, compared with normal men.Conclusions: CCL11 may be helpful in diagnosing prostatic diseases, such as BPH and PCa.
Abstract
Purpose: CC-chemokine ligand 11 (CCL11; eotaxin-1), an eosinophil chemoat-tractant chemokine, has been proposed as a serum marker for prostate cancer (PCa) by two research groups. We investigated the usefulness of CCL11 in diagnosing prostatic diseases, such as benign prostatic hyperplasia (BPH) and PCa.Materials and Methods: CCL11 was measured in the sera of 139 men with BPH, 44 men with PCa, and 45 control men attending an outpatient health-screening clinic. A commercial enzyme-linked immunosorbent assay kit was used to measure CCL11.Results: CCL11 concentrations were significantly higher in men with BPH and PCa than in normal men (72.9±3.15 and 80.0±4.91 pg/ml vs. 57.6±8.24). In addition, a receiver operating characteristic (ROC) analysis of serum CCL11 levels showed that the areas under the ROC curves were 0.661 (p=0.001) and 0.654 (p=0.012) for BPH and PCa, respectively, compared with normal men.Conclusions: CCL11 may be helpful in diagnosing prostatic diseases, such as BPH and PCa.
참고문헌 (33)
- Matthews AN, "Eotaxin is required for the baseline level of tissue eosinophils", Proc Natl Acad Sci U S A, 95, pp.6273~6278 (1998)
- Solari R, "Chemokine receptors as therapeutic targets: why aren't there more drugs?", Eur J Pharmacol, 746, pp.363~367 (2015)
- Agarwal M, "CCL11(eotaxin-1) : a new diagnostic serum marker for prostate cancer", Prostate, 73, pp.573~581 (2013)
- Heidegger I, "Is Eotaxin-1 a serum and urinary biomarker for prostate cancer detection and recurrence?", Prostate, 75, pp.1904~1909 (2015)
- Daniella Bianchi-Frias, "The Effects of Aging on the Molecular and Cellular Composition of the Prostate Microenvironment", PLoS ONE, 5(9), pp.e12501~ (2010), Public Library of Science (PLoS)[DOI]
- Wei JT, "Urologic diseases in America project : benign prostatic hyperplasia", J Urol, 173, pp.1256~1261 (2005)
- Siegel R, "Cancer statistics, 2012", CA Cancer J Clin, 62, pp.10~29 (2012)
- St Sauver JL, "Inflammatory mechanisms associated with prostatic inflammation and lower urinary tract symptoms", Curr Prostate Rep, 6, pp.67~73 (2008)
- Sfanos KS, "Prostate cancer and inflammation : the evidence", Histopathology, 60, pp.199~215 (2012)
- Penna G, "Seminal plasma cytokines and chemokines in prostate inflammation : interleukin 8 as a predictive biomarker in chronic prostatitis", chronic pelvic pain syndrome and benign prostatic hyperplasia, 2007, pp.51, 524~533
- Bouraoui Y, "Pro-inflammatory cytokines and prostate-specific antigen in hyperplasia and human prostate cancer", Cancer Detect Prev, 32, pp.23~32 (2008)
- Macoska JA, "Pilot and feasibility study of serum chemokines as markers to distinguish prostatic disease in men with low total serum PSA", Prostate, 68, pp.442~452 (2008)
- Zhu F, "Eotaxin-1 promotes prostate cancer cell invasion via activation of the CCR3-ERK pathway and upregulation of MMP-3 expression", Oncol Rep, 31, pp.2049~2054 (2014)
- Kelly RS, "Metabolomic biomarkers of prostate cancer: prediction, diagnosis, progression, prognosis, and recurrence", Cancer Epidemiol Biomarkers Prev, 25, pp.887~906 (2016)
- Collin SM, "Prostate-cancer mortality in the USA and UK in 1975-2004 : an ecological study", Lancet Oncol, 9, pp.445~452 (2008)
- Miller DC, "Missing the mark on prostatespecific antigen screening", JAMA, 306, pp.2719~2720 (2011)
- Cazares LH, "Molecular pathology of prostate cancer", Cancer Biomark, 9, pp.441~459 (2010)
- Martin NE, "Prognostic determinants in prostate cancer", Cancer J, 17, pp.429~437 (2011)
- Netto GJ, "Emerging critical role of molecular testing in diagnostic genitourinary pathology", Arch Pathol Lab Med, 136, pp.372~390 (2012)
- Salami SS, "Combining urinary detection of TMPRSS2 : ERG and PCA3 with serum PSA to predict diagnosis of prostate cancer", Urol Oncol, 31, pp.566~571 (2013)
- Gerber BO, "Functional expression of the eotaxin receptor CCR3 in T lymphocytes co-localizing with eosinophils", Curr Biol, 7, pp.836~843 (1997)
- Uguccioni M, "High expression of the chemokine receptor CCR3 in human blood basophils. Role in activation by eotaxin, MCP-4, and other chemokines", J Clin Invest, 100, pp.1137~1143 (1997)
- Sallusto F, "Selective expression of the eotaxin receptor CCR3 by human T helper 2 cells", Science, 277, pp.2005~2007 (1997)
- Levina V, "Role of eotaxin-1 signaling in ovarian cancer", Clin Cancer Res, 15, pp.2647~2656 (2009)
- Waddell A, "Intestinal CCL11 and eosinophilic inflammation is regulated by myeloid cell-specific RelA", p65 in mice, 2013, pp.190, 4773~4785
- Nolen BM, "Targeting CCL11 in the treatment of ovarian cancer", Expert Opin Ther Targets, 14, pp.157~167 (2010)
- Chao PZ, "Plasma RANTES and eotaxin levels are correlated with the severity of chronic rhinosinusitis", Eur Arch Otorhinolaryngol, 269, pp.2343~2348 (2012)
- Geiger SM, "Serum CCL11(eotaxin-1)and CCL17(TARC)are serological indicators of multiple helminth infections and are driven by Schistosoma mansoni infection in humans", Trop Med Int Health, 18, pp.750~760 (2013)
- Byers LA, "Serum signature of hypoxia-regulated factors is associated with progression after induction therapy in head and neck squamous cell cancer", Mol Cancer Ther, 9, pp.1755~1763 (2010)
- Johrer K, "Up-regulation of functional chemokine receptor CCR3 in human renal cell carcinoma", Clin Cancer Res, 11, pp.2459~2465 (2005)
- Egler RA, "An integrated proteomic approach to identifying circulating biomarkers in high-risk neuroblastoma and their potential in relapse monitoring", Proteomics Clin Appl, 5, pp.532~541 (2011)
- Shurin GV, "Dynamic alteration of soluble serum biomarkers in healthy aging", Cytokine, 39, pp.123~129 (2007)
- Villeda SA, "The ageing systemic milieu negatively regulates neurogenesis and cognitive function", Nature, 477, pp.90~94 (2011)